title: Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
abstract: Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-DOTATATE PET/CT.
authors.affiliation: From the *Department of Nuclear Medicine, Ankara University Medical School, Ankara; and Departments of †Nuclear Medicine and ‡Endocrinology and Metabolism and §Medical Oncology, Ondokuz Mayis University Medical School, Samsun, Turkey.
authors.forename: Elgin
authors.initials: E
authors.lastname: Ozkan
authors.forename: Cigdem
authors.initials: C
authors.lastname: Soydal
authors.forename: Sibel
authors.initials: S
authors.lastname: Ucak Semirgin
authors.forename: Oktay
authors.initials: O
authors.lastname: Yapici
authors.forename: Aysegul
authors.initials: A
authors.lastname: Atmaca
authors.forename: Guzin
authors.initials: G
authors.lastname: Demirag
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068338:Everolimus / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus